The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

Sitryx Therapeutics, a clinical-stage biopharmaceutical company, announced participation in three major investor conferences (Jefferies Global Healthcare, J.P. Morgan European Healthcare Forum, and Evercore Emerging Private Biotech) in June 2026. The company is developing novel oral therapies for autoimmune and inflammatory diseases, with lead candidate SYX-5219 (PKM2 modulator) showing safety and efficacy in Phase 1a trials, and a GLS1 inhibitor nominated for clinical development in asthma.

Sitryx Therapeutics announced positive Phase 1a trial results for SYX-5219, a first-in-class oral pyruvate kinase M2 (PKM2) modulator for atopic dermatitis. The drug demonstrated safety, tolerability, target engagement, and evidence of systemic immunomodulation with reduced CCL17/TARC biomarker levels. A Phase 1b trial in adults with moderate to severe atopic dermatitis is underway with data expected by year-end 2026.

GSK entered an exclusive strategic collaboration with Sino Biopharmaceutical to accelerate bepirovirsen, an investigational hepatitis B treatment, in mainland China. The drug is under priority regulatory review in China and showed positive Phase 3 trial data. GSK will retain marketing authorization and regulatory responsibility while CTTQ handles distribution and promotional activities. Additionally, GSK announced the final tranche of its £2 billion share repurchase program.

The antibiotic resistance market is projected to grow from USD 9.78 billion in 2026 to USD 12.72 billion by 2031 at a 5.4% CAGR, driven by rising multidrug-resistant infections and innovations in rapid diagnostics and novel antimicrobials. North America leads the market while Asia-Pacific emerges as a high-growth region.

A Delaware Chancery Court dismissed Tesaro's (GSK subsidiary) anticipatory breach of contract claim against AnaptysBio, rejecting requests for royalty reductions on Jemperli. The ruling affirms Anaptys has not repudiated the collaboration agreement and validates the company's efforts to protect its contractual rights. A trial is scheduled for July 14-17, 2026, where Anaptys will pursue claims that Tesaro/GSK materially breached the agreement and seek potential reversion of Jemperli.

The omics-based clinical trials market is experiencing robust growth, expanding from $31.71 billion in 2025 to $34.49 billion in 2026 with an 8.8% CAGR, and projected to reach $47.78 billion by 2030. Growth is driven by increasing demand for personalized medicine, genomics advancements, AI-enabled patient recruitment, and biomarker-driven trial designs. North America leads the market while Asia-Pacific shows rapid expansion potential.

Over 65 pharmaceutical companies are advancing 75+ pipeline COPD drugs, with the treatment landscape evolving beyond traditional bronchodilators toward targeted biologics and anti-inflammatory therapies. Recent clinical trial successes include AstraZeneca's tozorakimab meeting primary endpoints in Phase III trials, and multiple companies progressing novel candidates through various development stages.

ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers, has appointed Melissa Faris as an independent Non-Executive Director. Faris brings extensive experience from GSK and OMass Therapeutics, with a 20-year career in respiratory medicines and immunology business development. The appointment strengthens ENA's board as the company advances clinical development of its lead product INNA-051, a nasal dry powder designed to reduce viral respiratory infections in at-risk populations.

The SLE and LN market is projected to grow from $2.4 billion in 2024 to $5.9 billion by 2034 (9.6% CAGR), driven by 10 late-stage pipeline drugs offering improved safety and efficacy over current generic treatments. However, growth faces headwinds from biosimilar competition and high treatment costs limiting adoption rates.

The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.